CytomX Therapeutics (CTMX) Scheduled to Post Quarterly Earnings on Thursday

CytomX Therapeutics (NASDAQ:CTMX) is set to post its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect CytomX Therapeutics to post earnings of ($0.16) per share for the quarter.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). CytomX Therapeutics had a negative return on equity of 27.44% and a net margin of 9.27%. The firm had revenue of $25.12 million for the quarter, compared to analysts’ expectations of $21.79 million. During the same period in the prior year, the firm posted ($0.02) earnings per share. On average, analysts expect CytomX Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CytomX Therapeutics Stock Up 4.5 %

CytomX Therapeutics stock traded up $0.04 during midday trading on Friday, reaching $1.04. The stock had a trading volume of 397,419 shares, compared to its average volume of 2,584,491. CytomX Therapeutics has a 52-week low of $0.99 and a 52-week high of $5.85. The company has a fifty day moving average of $1.16 and a 200 day moving average of $1.50. The firm has a market cap of $81.28 million, a price-to-earnings ratio of 7.11 and a beta of 1.04.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “neutral” rating on shares of CytomX Therapeutics in a report on Friday, September 13th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $5.77.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.